Filana Therapeutics reports Q3 2026 financial results
It posts a $10.7 million net loss and holds $47.0 million in cash with no debt. The FDA lifted the clinical hold on simufilam, with Phase 2a screening expected by Q1 2027.
See the latest news and media coverage for Filana Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing treatments for central nervous system disorders
filanatx.comLast updated
In short: Filana Therapeutics advanced simufilam toward a Phase 2a epilepsy study after FDA lifted its clinical hold.
It posts a $10.7 million net loss and holds $47.0 million in cash with no debt. The FDA lifted the clinical hold on simufilam, with Phase 2a screening expected by Q1 2027.
The clearance enables a Phase 2a study in TSC-related epilepsy, with patient screening expected to begin by the first quarter of 2027.
The company posts an $8.6 million net loss and holds $82.7 million in cash while paying a $31.25 million litigation settlement to resolve securities claims.
The company reported a net loss of $10.3 million and provided updates on its TSC program's regulatory progress with the FDA.
Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold ...
Such statements speak only as of ... development of simufilam; risks inherent in drug discovery and development; and other risks specific to Filana Therapeutics, Inc...
AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies...
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies...
Track Filana Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Filana Therapeutics and other trending companies.